Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyvox Drug Interactions Draw Second Safety Communication From FDA, But Pfizer Says Info Isn't New

Executive Summary

FDA and Pfizer appear to disagree over whether new information about harmful drug interactions between Pfizer’s antibiotic Zyvox (linezolid) and serotonergic antidepressants, including multiple deaths, led the agency to issue a drug safety communication.

You may also be interested in...



Blood Clot Risks For Yasmin, Yaz, Ortho Evra Get Panel Review After FDA Epidemiology Study

FDA's Reproductive Health Drugs and Drug Safety and Risk Management advisory committees will discuss the benefits and risks of drospirenone-containing drugs and the Ortho Evra patch at a two-day meeting in December.

No End In Sight: Pharma Companies Continue To Face Government Probes

FDA Contraindicates Three Gadolinium Imaging Agents In Severe Kidney Disease

However, the agency says all seven gadolinium-based contrast agents used in MRI and MRA procedures present a risk of nephrogenic systemic fibrosis.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel